Physician profile
Williams B Burrows
NPI 1114924867
$1,351.08
in general payments reported to CMS, 2019-2025
24 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $133 · 2021: $367 · 2022: $163 · 2023: $223 · 2024: $199 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $274.28 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $131.97 | 2020-2023 | Mounjaro, Trulicity |
| Amgen INC. | $129.84 | 2019-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $121.65 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $73.36 | 2020-2021 | |
| Dexcom, INC. | $68.28 | 2023-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $58.88 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $57.66 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.98 | 2022 | |
| Novo Nordisk INC | $52.69 | 2021-2023 | Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $41.45 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $37.28 | 2020-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.93 | 2021-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $33.99 | 2024-2025 | Voquezna |
| Pfizer INC. | $30.18 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.39 | 2023 | |
| Amarin Pharma, INC. | $19.02 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.52 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.04 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.21 | 2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $15.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.96 | 2021 | |
| Glaxosmithkline, LLC. | $14.63 | 2023 | Shingrix |
| Allergan, INC. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Williams Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.